The Sentinel Initiative mandated by the Food and Drug Administration will lead to an enormous number of studies being planned post-market that will require analyzing and combining data from several different studies. The proposed project will address this challenge through developing new and flexible methods for meta-analysis using a variety of models, including models for binary and discrete data, models for longitudinal data, and models for time-to-event data. A related issue that will also be addressed is design, sample size, and power considerations using these types of meta-analytic models. Such models and data collected post-market can be quite useful in designing future clinical studies such as non-inferiority, equivalence, and superiority cancer clinical trials. The proposed project will also develop methods for metaanalytic studies of diagnostic tests to facilitate evidence-based medicine. We will also create flexible and robust methodology for accurately comparing rare adverse event rates in cancer for different drugs and for determining how those rates are affected by important prognostic factors. The proposed project will also explore statistical methods for the analysis of large cancer data sets for calibrating treatment dose in the presence of potentially conflicting factors, such as length and quality of life and economic costs. We will explore these tradeoffs rigorously, using a utility based approach traditionally employed in the analysis of health policy at the population level. The proposed statistical methodology will be broadly applicable to complex, large scale, data sets arising in phase III clinical trials and post-marketing studies.

Public Health Relevance

The proposed statistical methodology will be broadly applicable to the statistical analysis and interpretation of complex, large scale, data sets arising in phase III clinical trials and post-marketing studies. The research will improve public health be facilitating discovery of important benefits and risks of cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142538-02
Application #
8245191
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
2
Fiscal Year
2011
Total Cost
$120,354
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Zhou, Jie; Zhang, Jiajia; Lu, Wenbin (2018) Computationally Efficient Estimation for the Generalized Odds Rate Mixture Cure Model with Interval-Censored Data. J Comput Graph Stat 27:48-58
Butler, Emily L; Laber, Eric B; Davis, Sonia M et al. (2018) Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules. Biometrics 74:18-26
Wong, Kin Yau; Zeng, Donglin; Lin, D Y (2018) Efficient Estimation for Semiparametric Structural Equation Models With Censored Data. J Am Stat Assoc 113:893-905
Wang, Charlotte; Tzeng, Jung-Ying; Wu, Pei-Zhen et al. (2018) Reexamining Dis/Similarity-Based Tests for Rare-Variant Association with Case-Control Samples. Genetics 209:105-113
Wu, Jing; Ibrahim, Joseph G; Chen, Ming-Hui et al. (2018) Bayesian Modeling and Inference for Nonignorably Missing Longitudinal Binary Response Data with Applications to HIV Prevention Trials. Stat Sin 28:1929-1963
Li, Zhiguo; Wang, Xiaofei; Wu, Yuan et al. (2018) Sample size calculation for studies with grouped survival data. Stat Med 37:3904-3917
Wang, Chun; Chen, Ming-Hui; Wu, Jing et al. (2018) Online updating method with new variables for big data streams. Can J Stat 46:123-146
Ni, Ai; Cai, Jianwen (2018) Tuning Parameter Selection in Cox Proportional Hazards Model with a Diverging Number of Parameters. Scand Stat Theory Appl 45:557-570
Teran Hidalgo, Sebastian J; Wu, Michael C; Engel, Stephanie M et al. (2018) Goodness-Of-Fit Test for Nonparametric Regression Models: Smoothing Spline ANOVA Models as Example. Comput Stat Data Anal 122:135-155
Jung, Sin-Ho (2018) Phase II cancer clinical trials for biomarker-guided treatments. J Biopharm Stat 28:256-263

Showing the most recent 10 out of 549 publications